Breast Cancer Therapeutics Market Size By Therapy (Targeted Therapy, Hormonal Therapy, Chemotherapy, Immunotherapy), Industry Analysis Report, Regional Outlook, COVID-19 Impact Analysis, Competitive Market Share & Forecast, 2022 - 2028

Industry Overview

Breast Cancer Therapeutics Market size exceeded USD 25.5 billion in 2021 and is estimated to register around 8% CAGR between 2022 and 2028. The growing incidence of breast cancer is amongst the major factors stimulating the overall market growth. According to the International Agency for Research on Cancer (WHO), in 2020, the incidence of breast cancer was 2,261,419, accounting for approximately 11.7% of the total cancer cases globally.
 

To get more details on this report: Request Free Sample PDF
 

Further, the disease accounted for 684,996 mortalities in 2020. Thus, the high incidence and mortality rate associated with breast cancer is expected to render significant impact, driving the market expansion.
 

Breast cancer therapeutics can be defined as the treatment or management of breast cancer using therapeutic approach & drugs such as the targeted therapy, chemotherapy, hormonal therapy, and other therapeutics. These therapeutics abduct the growth and multiplication of cancerous cells by disrupting certain proteins or DNA.
 

However, several side effects associated with the use of breast cancer therapeutics along with the high cost of drugs may negatively impact the breast cancer therapeutics industry growth. Owing to adverse effects of chemotherapy, concerns have been raised regarding the heightened risk of chronic & acute effects among breast cancer patients. These patients receiving chemotherapy frequently experience side effects such as cardiac toxicity, pneumonitis (RP), arm lymph edema, retherapyive ysfunction, neuropathy, and skin changes among other complications.

Further, the adjuvant treatment may lead to bowel disturbance, neutropenia, radiation dermatitis, fatigue, and other complications. The host of negative effects associated with the breast cancer therapeutics may limit the therapy adoption and hamper the market demand.
 

The COVID-19 pandemic emerged as an unprecedented health concern and has slowed down the breast cancer therapeutics market growth. The coronavirus outbreak has disrupted the global economy, inflicting economic burden and financial adversities. Many sectors have witnessed drastic transition including the healthcare sector. Hospital admissions regarding COVID-19 affected patients were prioritized, with other medical procedures postponed.

According to the National Centers for Biotechnology Information (NCBI) article, in 2021, the COVID-19 pandemic caused delays in the screening and treatment of breast cancer patients owing to fear of infection and lockdown. The study reported a 15% drop in breast cancer patients admitted during the coronavirus outbreak. Similarly, as per the BMC Journal of Hematology and Oncology, the initial phase of pandemic hampered the Dutch national screening program and inflicted substantial burden on health care services that lead to delay in diagnosis and treatment of breast cancer patients. Pertaining to these developments, the breast cancer therapeutics market is projected to witness a slightly slow growth.
 

However, the rising incidence of breast cancer and increased mortality rate among breast cancer patients with acquired COVID-19 infection are expected to uplift the market size. Further, the reducing COVID-19 cases and initiatives taken by the authorities to facilitate the treatment of breast cancer patients would further benefit the market statistics. As a result, the market witnessed slow growth owing to delayed breast cancer diagnosis and treatment, although the industry is expected to follow the growth trajectory in the coming years.
 

Implementation of breast cancer awareness and screening programs is set to prove beneficial for the business scenario

Initiation of breast cancer awareness and screening programs by the regional government authorities to curb the mortality rates associated with breast cancer is anticipated to prove conducive for the market statistics. Breast cancer therapeutics are increasingly effective while treating breast cancer and delivers more than 90% survival probabilities, especially when the disease is diagnosed at an early stage. As per the NCBI article, in 2017, breast cancer screening programs aid in early detection, prevention of risk factors, optimal treatment to lower the morbidity, and promote survival rate. Thus, in order to induce the practice of timely cancer screening for early diagnosis, several local government agencies regulate and offer breast cancer screening programs across numerous countries.
 

Moreover, adoption of breast cancer awareness campaigns by public organizations is projected to promote the education regarding breast cancer and breast cancer therapeutics. For instance, the National Breast Cancer Foundation initiated “October as a Breast Cancer Awareness Month”, a campaign to drive awareness concerning the impact of breast cancer. Such initiatives are expected to encourage the diagnosed breast cancer patients to opt for optimal breast cancer therapeutics, further driving the survival rate of breast cancer therapeutics.
 

Potential of combination with other therapies, personalized approaches to enhance clinical outcomes, and novel advancements are anticipated to stimulate the business outlook

To get more details on this report: Request Free Sample PDF
 

Based on the therapy, the market is segmented as targeted therapy, hormonal therapy, chemotherapy, and immunotherapy. The targeted therapy segment accounted for more than 71% market share and is projected to register more than 8.4% CAGR from 2022-2028. This dominant market share is owing to the versatility to combine with other therapies, the emergence of personalized approach to enhance clinical outcomes, and novel advancements. Ongoing clinical studies have widened the scope of targeted therapies to include multiple molecules in targetable pathways including the epidermal growth factor receptor (EGFR), poly (adenosine diphosphate-ribose) polymerase (PARP), and cyclin-dependent kinase 4/6 (CDK4/6).
 

Further, developments in treatment for metastatic hormone receptor-positive breast cancer have promoted the use of targeted therapies. Majority of the treatment guidelines, including the National Comprehensive Cancer Network suggests the use of targeted therapeutic options with artificial intelligence or selective ER modulators rather than chemotherapy. Thus, the heightened use and increased preference for targeted therapy is expected to drive the demand for breast cancer therapeutics.
 

The high incidence of breast cancer in the North America region is set to boost the regional business landscape

To get more details on this report: Request Free Sample PDF
 

U.S. breast cancer therapeutics market is anticipated to surpass USD 15.8 billion by 2028. This dominant market share is attributable to several factors such as the high incidence of breast cancer, steadily rising disease burden, and presence of major market players among others. According to the Breast Cancer Organizations statistics, as of January 2022, breast cancer affects more than 3.8 million American women. The statistics indicate that in the year 2022, around 30% of newly diagnosed cancers among women are estimated to be breast cancer cases.
 

The Globocan 2020 reported that the incidence of breast cancer was 253,465 cases in the U.S. Thus, the high incidence and prevalence of breast cancer inflicts significant mortality along with disease burden. The rising disease burden in the country is anticipated to promote the demand for breast cancer therapeutics. Furthermore, the presence of major market players and favorable reimbursement scenario for breast cancer treatment would drive the acceptance rate of breast cancer therapeutics. Thus, owing to the above-mentioned factors, the market growth in the U.S. is estimated to expedite in the coming years.

Strategies adopted by major market players will boost the industry landscape

Some of the major industry players involved in the breast cancer therapeutics industry include AstraZeneca, Eli Lilly, & Co., Pfizer, BMS, Novartis, Amgen, Roche, and Merck among others. These market players focus on strategic partnerships, new therapy launch & commercialization for business expansion. Furthermore, these industry players are heavily investing in research that allows them to introduce innovative therapies and garner maximum revenue in the market.
 

Recent industry developments:

• In November 2021, AstraZeneca and Merck Sharpe & Dohme’s supplemental New Drug Application (sNDA) for Lynparza (olaparib) was granted Priority Review in the U.S. intended for the adjuvant treatment of patients suffering with BRCA-mutated (BRCAm) HER2-negative high-risk early breast cancer. Lynparza is currently being jointly developed & commercialized by AstraZeneca and MSD. This strategic collaboration helped both the company to gain competitive advantage and strengthen their market position.
   
• In July 2021, Merck, & Co., Inc received the U.S. FDA approval for its KEYTRUDA (pembrolizumab) for treatment of patients with high-risk early-stage triple-negative breast cancer in combination with chemotherapy. This approval assisted the company in bolstering its breast cancer therapeutics portfolio and driving the market share.
   

Breast cancer therapeutics market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2017 to 2028, for the following segments:

Click here to Buy Section of this Report

By Therapy

• Targeted therapy
• Hormonal therapy
• Chemotherapy
• Immunotherapy

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE